few years back we tried to do a project on use based pricing as well as dose based pricing in Europe with a large data company...but we failed to get the level of data that could have helped form up the hypothesis on low does drugs in immunotherapy...unless the clinician pushes this there is no incentive for the pharma company to seek a low dose regime...sad
Happening in the US as well…Smat folks at AON and Thyme Care. https://www.hmpgloballearningnetwork.com/site/jcp/field/operationalizing-weight-based-dosing-pembrolizumab-opportunities-and-challenges#:~:text=The%20operational%20lift%20of%20executing,and%20actuarial%20and%20reinsurance%20services.
few years back we tried to do a project on use based pricing as well as dose based pricing in Europe with a large data company...but we failed to get the level of data that could have helped form up the hypothesis on low does drugs in immunotherapy...unless the clinician pushes this there is no incentive for the pharma company to seek a low dose regime...sad